RxDoctor Payments Data

J Christensen, MD

Internal Medicine · Richmond, VANPI 1639158066

Payments from drug & device makers

$4,849in general payments, 2019–2025

Across 282 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$817
  • Novo Nordisk$546
  • Pfizer$358
  • Lilly USA, LLC$350
  • Boehringer Ingelheim$265
  • Amgen$250
  • plus $2K from 45 others

What the payments were for

  • Food & beverage$4,67896%
  • Education$1553%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,849 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$294,218
Medicare patients
714
Services billed
4,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$256,851
JardianceEmpagliflozin60$92,146
XareltoRivaroxaban69$83,690
OzempicSemaglutide42$59,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$51,802
TrulicityDulaglutide36$47,394
JanuviaSitagliptin Phosphate31$38,455
MyrbetriqMirabegron60$34,176
MounjaroTirzepatide15$23,235
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$21,613
LinzessLinaclotide27$16,143
VraylarCariprazine Hcl11$15,339
NamzaricMemantine Hcl/Donepezil Hcl19$10,988
Spiriva HandihalerTiotropium Bromide14$10,976
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$10,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$358$256,851232 claims
Boehringer IngelheimJardiance$265$92,14660 claims
Johnson & JohnsonXarelto$12$83,69069 claims
Lilly USA, LLCTrulicity, Mounjaro$350$70,62851 claims
Novo NordiskOzempic$546$59,92442 claims
GSKTrelegy Ellipta, Arexvy$103$58,54477 claims
AbbVieLinzess, Vraylar, Namzaric, Synthroid, Lumigan$817$51,592172 claims
MerckJanuvia, Janumet Xr$94$48,35645 claims
Astellas Pharma US IncMyrbetriq$99$34,17660 claims
AstraZenecaFarxiga$105$7,78313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$23$6,09412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →